Gastric juice protein is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-11-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | About 1419.5 Da | Calculated from the fifteen-residue sequence |
| Residue count | 15 amino acids | Single-letter sequence GEPPPGKPADDAGLV |
| Compound class | Synthetic peptide | Produced by solid-phase synthesis |
| Synonyms | BPC 157; pentadecapeptide BPC 157 | Naming varies across suppliers and papers |
| Appearance | White to off-white powder | Typical form of the lyophilized material |
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
is constant), the relation Qp = Q1p1 = Q2p2 can be obtained. Over a short section of the pipe, the gas flowing through the pipe can be assumed to be incompressible so that Poiseuille law can be used locally,
Whilst being unable to play in 2014 due to a hip flexor injury, Watson did commentary work for the Seven Network as a boundary rider for one match; he later returned in 2019 for a home-and-away match and final. He also filled in for co-host Craig Hutchison on the episode of Footy Classified immediately following the final home-and-away round of the 2017 season, and was a guest panellist on Talking Footy in 2019. He joined Seven's commentary team on a more permanent basis in 2020. While serving his suspension in 2016, Watson worked at Hole in the Wall, a coffee shop in New York City. During his retirement speech, Watson said that he had several United States–based business interests, including two café-style venues, a gym and a buyers' advocacy business, that he wanted to focus on upon retiring. In June 2019, Watson participated in the Big Freeze at the 'G alongside several former AFL footballers and Australian sportspeople to raise money for the Cure for MND Foundation.
Microgravity is the condition of low gravity found in outer space. Some of the major physiological implications that are associated with microgravity are bone loss, immunosuppression, enlargement of bones, muscle loss and movement of body fluids towards the head, spaceflight osteopenia, decrease in the function of cardiovascular system functions, decreased production of red blood cells, balance disorders, and also weaken the human immune system. In addition to this, fluid distribution is increased in the upper body due to the body's ability to pump blood faster to the upper body in microgravity conditions, known as the cephalad fluid shift. In addition, muscle regeneration protein levels have been estimated to vary due to microgravity conditions, including myostatin, activin A, and certain cytokines (e.g. IL-6, IL-10, IL-1ra), which are currently used as targets for drug delivery applications. The effects of microgravity has also investigated in wound healing processes, especially with the behavior of cell populations, such as fibroblasts. For cell studies, a Rotary Cell Culture System was used to mimic cell conditions in microgravity, where the bioreactor rotates horizontally, causing cell sedimentation in the vessel to be offset by the rotating fluid. This results in this light falling of cells, simulated in a microgravity environment. Studies showed a rearrangement of microtubules in cells due to microgravity, forming a dense, puzzled, network, unlike fibroblasts in a normal environment, which exhibit radial parallel formations.
The styrene monomer (from which polystyrene is made) is "reasonably anticipated to be a human carcinogen". Styrene is "generally found in such low levels in consumer products that risks aren't substantial". Polystyrene which is used for food contact may not contain more than 1% (0.5% for fatty foods) of styrene by weight. Styrene oligomers in polystyrene containers used for food packaging have been found to migrate into the food. Another Japanese study conducted on wild-type and AhR-null mice found that the styrene trimer, which the authors detected in cooked polystyrene container-packed instant foods, may increase thyroid hormone levels. Whether polystyrene can be microwaved with food is controversial. Some containers may be safely used in a microwave, but only if labeled as such. Some sources suggest that foods containing carotene (vitamin A) or cooking oils must be avoided. Because of the pervasive use of polystyrene, these serious health related issues remain topical.
=== Cost === While the cost of the medication buprenorphine/naloxone is greater than buprenorphine alone, one analysis predicted the overall costs would be less in the United States due to a lower risk of misuse.
Sources: en.wikipedia.org
=== Early clinical trials, supply and the transfer to BMS === Phase I clinical trials began in April 1984, and the decision to start Phase II trials was made a year later. These larger trials needed more bark and collection of a further 12,000 pounds was commissioned, which enabled some phase II trials to begin by the end of 1986. But by then it was recognized that the demand for taxol might be substantial and that more than 60,000 pounds of bark might be needed as a minimum. This unprecedentedly large amount brought ecological concerns about the impact on yew populations into focus for the first time, as local politicians and foresters expressed unease at the program. The first public report from a phase II trial in May 1988 showed promising effects in melanoma and refractory ovarian cancer. At this point, Gordon Cragg of the NCI's Natural Product Branch calculated the isolation of enough taxol to treat all the ovarian cancer and melanoma cases in the US would require the destruction of 360,000 trees annually. For the first time, serious consideration was given to the problem of supply.
==== Employee opposition to AI militarisation ==== In May 2026, workers at Google DeepMind's London headquarters voted to unionise, requesting joint representation by the Communication Workers Union (CWU) and Unite the Union. The unionisation drive was heavily motivated by ethical concerns regarding Google's military-industrial AI contracts, specifically the provision of AI technology to the US Department of Defense and the Israeli military.
== Taxonomy == The first scientific description of D. cinnabari was made during a survey of Socotra led by Lieutenant Wellsted of the East India Company in 1835. It was first named Pterocarpus draco, but in 1880 the Scottish botanist Isaac Bayley Balfour made a formal description of the species and renamed it as Dracaena cinnabari. Of between 60 and 100 Dracaena species, D. cinnabari is one of only six species that grow as a tree. Along with other plants on Socotra, D. cinnabari is thought to have derived from the Tethyan flora. It is considered a remnant of the Mio-Pliocene Laurasian subtropical forests that are now almost extinct because of the extensive desertification of North Africa.
Humans express two distinct isozymes of IMPDH encoded by two distinct genes, IMPDH1 and IMPDH2. Both isozymes contain 514 residues, have an 84% similarity in peptide sequence, and have similar kinetic properties. Both isozymes are constitutively expressed in most tissues, but IMPDH1 is predominately expressed in the spleen, retina, and peripheral blood leukocytes. IMPDH1 is generally expressed constitutively at low levels, and IMPDH2 is generally upregulated in proliferating cells and neoplastic tissues. Homozygous IMPDH1 knockout mice demonstrate a mild retinopathy in which a slow, progressive form of retinal degeneration gradually weakens visual transduction, while homozygous IMPDH2 knockout mice display embryonic lethality.
== Further reading == Higgins SJ, Hames BD (1999). Protein Expression: A Practical Approach. Oxford University Press. ISBN 978-0-19-963623-5. Baneyx, François (2004). Protein Expression Technologies: Current Status and Future Trends. Garland Science. ISBN 978-0-9545232-5-1.
Sources: en.wikipedia.org
=== Genetic susceptibility of certain breeds === This list of risk factors for canine diabetes is taken from the genetic breed study that was published in 2007. Their "neutral risk" category should be interpreted as insufficient evidence that the dog breed genetically shows a high, moderate, or a low risk for the disease. All risk information is based only on discovered genetic factors.
== External links == "État civil de Paris en ligne" [Paris civil status online] (in French). Archived from the original on January 5, 2020. "Commission de reconstitution de l'état civil parisien (1875-1897)" [Commission for the reconstitution of Parisian civil status (1875-1897)] (PDF) (in French). Archived from the original (PDF) on January 1, 2022. "Inventaire des registres de catholicité de baptêmes, mariages et sépultures des églises parisiennes de 1792 à 1909 conservés aux archives de Paris (collection de l'archevêché) et dans les paroisses" [Inventory of Catholic registers of baptisms, marriages and burials in Paris churches from 1792 to 1909 held by the Archives de Paris (archbishop's collection) and parishes.] (PDF) (in French). Archived from the original (PDF) on February 21, 2024. "Diocèse de Paris, formulaire de recherche pour trouver la paroisse dont dépend une adresse parisienne" [Diocese of Paris, search form to find the parish of a Paris address] (in French). Archived from the original on March 9, 2014. "Registre de relevés d'actes de baptêmes, mariages et sépultures de l'église Saint-Sulpice de Paris pour la période 1537-1748" [Register of records of baptisms, marriages and burials from the Saint-Sulpice church in Paris for the period 1537-1748] (in French). Archived from the original on December 4, 2013. "Archives numérisées de l'AP-HP Assistance Publique Hôpitaux de Paris" [Digital archives of AP-HP Assistance Publique Hôpitaux de Paris] (in French). Archived from the original on October 22, 2013.
Enzymes can use cofactors as 'helper molecules'. Coenzymes are referred to those non-protein molecules that bind with enzymes to help them fulfill their jobs. Mostly they are connected to the active site by non-covalent bonds such as hydrogen bond or hydrophobic interaction. But sometimes a covalent bond can also form between them. For example, the heme in cytochrome C is bound to the protein through thioester bond. In some occasions, coenzymes can leave enzymes after the reaction is finished. Otherwise, they permanently bind to the enzyme. Coenzyme is a broad concept which includes metal ions, various vitamins and ATP. If an enzyme needs coenzyme to work itself, it is called an apoenzyme. In fact, it alone cannot catalyze reactions properly. Only when its cofactor comes in and binds to the active site to form holoenzyme does it work properly. One example of the coenzyme is Flavin. It contains a distinct conjugated isoalloxazine ring system. Flavin has multiple redox states and can be used in processes that involve the transfer of one or two electrons. It can act as an electron acceptor in reaction, like the oxidation of NAD to NADH, to accept two electrons and form 1,5-dihydroflavin. On the other hand, it can form semiquinone(free radical) by accepting one electron, and then converts to fully reduced form by the addition of an extra electron. This property allows it to be used in one electron oxidation process.
Electrochemotherapy is the combined treatment in which injection of a chemotherapeutic drug is followed by application of high-voltage electric pulses locally to the tumor. The treatment enables the chemotherapeutic drugs, which otherwise cannot or hardly go through the membrane of cells (such as bleomycin and cisplatin), to enter the cancer cells. Hence, greater effectiveness of antitumor treatment is achieved. Clinical electrochemotherapy has been successfully used for treatment of cutaneous and subcutaneous tumors irrespective of their histological origin. The method has been reported as safe, simple and highly effective in all reports on clinical use of electrochemotherapy. According to the ESOPE project (European Standard Operating Procedures of Electrochemotherapy), the Standard Operating Procedures (SOP) for electrochemotherapy were prepared, based on the experience of the leading European cancer centres on electrochemotherapy. Recently, new electrochemotherapy modalities have been developed for treatment of internal tumors using surgical procedures, endoscopic routes or percutaneous approaches to gain access to the treatment area.
The temperature at which the Leidenfrost effect appears is difficult to predict. Even if the volume of the drop of liquid stays the same, the Leidenfrost point may be quite different, with a complicated dependence on the properties of the surface, as well as any impurities in the liquid. Some research has been conducted into a theoretical model of the system, but it is quite complicated. The effect was also described by the Victorian steam boiler designer, William Fairbairn, in reference to its effect on massively reducing heat transfer from a hot iron surface to water, such as within a boiler. In a pair of lectures on boiler design, he cited the work of Pierre Hippolyte Boutigny (1798–1884) and Professor Bowman of King's College, London, in studying this. A drop of water that was vaporized almost immediately at 168 °C (334 °F) persisted for 152 seconds at 202 °C (396 °F). Lower temperatures in a boiler firebox might evaporate water more quickly as a result; compare Mpemba effect. An alternative approach was to increase the temperature beyond the Leidenfrost point. Fairbairn considered this, too, and may have been contemplating the flash steam boiler, but considered the technical aspects insurmountable for the time. The Leidenfrost point may also be taken to be the temperature for which the hovering droplet lasts longest. It has been demonstrated that it is possible to stabilize the Leidenfrost vapor layer of water by exploiting superhydrophobic surfaces.
Sources: en.wikipedia.org
It is a synthetic peptide. Its design was inspired by a fragment of a protein found in human gastric juice, but the fifteen-amino-acid molecule itself is made in a laboratory and is not a normal component of food or of human tissue in appreciable amounts.
The number is an internal laboratory designation from the research group that first described the fragment. It does not encode a molecular weight, a receptor target, or a measured biological effect, and it carries no meaning outside the naming history of the compound.
It contains fifteen amino acid residues and has a calculated mass of roughly 1419.5 daltons. That places it in the short-peptide range, well below the size of small proteins, which affects how it is synthesized, purified, and analyzed.
It is a synthetic peptide built from fifteen amino acids, with a mass of roughly 1419 daltons. The sequence is reported to match a fragment of a protein present in human gastric juice. It is not a naturally circulating hormone.